Effects of Levonorgestrel-Releasing Intrauterine System on Lymphangiogenesis of Adenomyosis
This study found that levonorgestrel-releasing intrauterine systems reduced lymphangiogenesis and lymphovascular density in the endometrial and myometrial tissues of adenomyosis patients compared to controls.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (34)
- Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis via openalex
- Decreased suppression of interleukin-6 after treatment with medroxyprogesterone acetate and danazol in endometrial stromal cells of women with adenomyosis via openalex
- Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging via openalex
- Endometrial Tissue in Myometrial Vessels not Associated with Menstruation via openalex
- Expression of interleukin-8 and monocyte chemotactic protein-1 in adenomyosis via openalex
- Hormonal treatments for adenomyosis via openalex
- Interleukin-8 in the Human Endometrium<sup>1</sup> via openalex
- Medical and surgical management of adenomyosis via openalex
- Pathophysiology of adenomyosis via openalex
- The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis via openalex
- TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD via openalex
- W2118372673 via openalex
- W2121039615 via openalex
- W2129081579 via openalex
- W2133376231 via openalex
- W2140625749 via openalex
- W2144750345 via openalex
- W2157162135 via openalex
- W2204640292 via openalex
- W2213819630 via openalex
- W4250972286 via openalex
- W6640342722 via openalex
- W1519030262 via openalex
- W6833068047 via openalex
- W1579697436 via openalex
- W1924639001 via openalex
- W2004186356 via openalex
- W2015908617 via openalex
- W2016941384 via openalex
- W2034089155 via openalex
- W2038354928 via openalex
- W2095619115 via openalex
- W2101766472 via openalex
- W2107623256 via openalex
Cited by (8)
- Clinical application of a simplified hysteroscopic LNG-IUD non-suture fixation in the treatment of adenomyosis 2024
- Long-term efficacy and safety of levonorgestrel releasing intrauterine system in the treatment of adenomyosis: evidence mapping 2024
- Histopathological characteristics of adenomyosis: structure and microstructure 2023
- Increased Angiogenesis and Lymphangiogenesis in Adenomyosis Visualized by Multiplex Immunohistochemistry 2022
- Long-term Efficacy and Safety of Levonorgestrel - releasing Intrauterine System in the Treatment of Adenomyosis: Evidence Mapping and Meta-analysis 2022
- Treatment of symptomatic adenomyosis with the levonorgestrel‐releasing intrauterine system 2019
- Minimally invasive treatment of adenomyosis 2018
- Current and Future Medical Treatment of Adenomyosis 2016
Source provenance
- europepmc
- last seen: 2026-06-20T06:14:18.781669+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:18:04.362919+00:00